NCT02260466View on ClinicalTrials.gov

Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.

NAActive, not recruitingINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 23, 2022

Study Completion Date

December 31, 2024

Conditions
Heart DiseaseAgingAmyloidosisAortic Valve Stenosis
Interventions
OTHER

a basal LV septum biopsy

During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion

Trial Locations (5)

31059

CHU de Toulouse, Toulouse

35000

Chu Rennes, Rennes

93200

Centre Cardiologique du Nord, Saint-Denis

94010

Hôpital Henri Mondor, Créteil

Unknown

CHU d'Amiens, Amiens

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Henri Mondor University Hospital

OTHER

lead

French Cardiology Society

OTHER

NCT02260466 - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement. | Biotech Hunter | Biotech Hunter